Moreover, the authors found that SPHK2 is responsible for autophagosome- and lysosome-mediated catabolism of the intracellular lipids, therefore SPHK2 has been suggested to be a novel target for the treatment of atherosclerosis (70). This evidence concerns the gene SPHK2 and atherosclerosis.